Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 16, 2026
- Prelude Therapeutics began Phase 1 enrollment for PRT13722 in HR+/HER2- breast cancer, expects proof-of-concept data in the 2nd half of 2027, and expects cash to fund operations into the second quarter of 2028.
- 10-Q report · filed Nov 16, 2026
- Prelude began Phase 1 enrollment for PRT13722 after September 2026 FDA clearance and entered an October 2026 clinical trial collaboration with Eli Lilly and Company to evaluate abemaciclib and imlunestrant combinations in HR+/HER2- breast cancer.
The audio replay and transcript follow the call.